Kiniksa Pharmaceuticals International PLC - Class A (KNSA) closed at $93.86 on November 6, 2026, up 6.2% from the previous close, on volume of 588,337 shares (30-day average 791,603).
Data as of November 6, 2026.
Kiniksa (KNSA) lifts 2026 ARCALYST revenue outlook to $1.045–$1.050B as Q3 sales reach $286.00M
Market Chameleon (Tue, 27-Oct 7:35 AM ET)
Kiniksa (KNSA) lifts 2026 ARCALYST outlook to $1.05B as Q3 revenue hits $286M
Market Chameleon (Tue, 27-Oct 3:41 AM ET)
Kiniksa Pharmaceuticals Reports Third Quarter 2026 Financial Results and Recent Portfolio Execution
Globe Newswire (Tue, 27-Oct 7:30 AM ET)
Kiniksa Pharmaceuticals to Report Third Quarter 2026 Financial Results on October 27, 2026
Globe Newswire (Thu, 22-Oct 4:01 PM ET)
Kiniksa Pharmaceuticals to Present at Wells Fargo 21st Annual Healthcare Conference
Globe Newswire (Fri, 4-Sep 4:01 PM ET)
Kiniksa Pharmaceuticals to Present at Canaccord Genuity 46th Annual Growth Conference
Globe Newswire (Fri, 7-Aug 4:01 PM ET)
Kiniksa Lifts ARCALYST Guidance Following 55% Growth and Positive Clinical Progress on KPL-387
Market Chameleon (Tue, 28-Jul 4:16 AM ET)
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.
Kiniksa Pharmaceuticals International PLC - Class A trades on the NASDAQ stock market under the symbol KNSA.
As of November 6, 2026, KNSA stock price climbed to $93.86 with 588,337 million shares trading.
KNSA has a beta of 0.09, meaning it tends to be less sensitive to market movements. KNSA has a correlation of 0.00 to the broad based SPY ETF.
KNSA has a market cap of $7.37 billion. This is considered a Mid Cap stock.
Last quarter Kiniksa Pharmaceuticals International PLC - Class A reported $286 million in Revenue and $.56 earnings per share. This beat revenue expectation by $26 million and exceeded earnings estimates by $.23.
In the last 3 years, KNSA traded as high as $98.48 and as low as $14.12.
The top ETF exchange traded funds that KNSA belongs to (by Net Assets): IWM, VTI, VB, VBK, IWO.
KNSA has outperformed the market in the last year with a price return of +139.8% while the SPY ETF gained +9.6%. KNSA has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +20.2% and +16.2%, respectively, while the SPY returned -4.2% and -3.8%, respectively.
KNSA support price is $85.51 and resistance is $91.17 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that KNSA shares will trade within this expected range on the day.
